NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » TOP 50 Pharmas » Eli Lilly & Co  1    
found files: 18
Eli Lilly & Co »04/05/2007 [Company watch]
Lilly Announces Senior Leadership Changes

Alex M. Azar II to join Lilly as senior vice president of corporate affairs and communications; Anne Nobles to assume role of chief compliance officer...   more»


Eli Lilly & Co »16/04/2007 [Company watch]
Lilly Reports Strong First-Quarter Results; Raises Full-Year Sales and EPS Guidance

Eli Lilly and Company (NYSE: LLY) today announced strong financial results for the first quarter of 2007 and raised its full-year sales and adjusted earnings per share guidance. First-Quarter Highlights * Sales increased 14 percent, to $4.226 billion....   more»


Eli Lilly & Co »06/06/2007 [Company watch]
BioVeda China to Receive $10 Million Investment from Lilly Asian Ventures

BioVeda China today announced a $10 Million investment from Lilly Asian Ventures. BioVeda China is the first international venture capital fund focusing on life-sciences investments in China. The investment has shown Lilly's commitment to expand its economic footprint in the fast growing life-science industry in China....   more»


Eli Lilly & Co »07/06/2007 [Company watch]
Lilly Announce $100 Million Investment in Research in China

Eli Lilly & Co, one of the world's leading pharmaceutical firms, plans to pour $100 million into China over the next five years to expand its drug research capacity in a bid to tap into the country's talent pool, its CEO said. The US drug maker will primarily beef up its research and development in biology, chemistry and clinical research areas, said John Lechleiter, president and CEO of Eli Lilly & Co....   more»


Eli Lilly & Co »06/06/2007 [Company watch]
BioVeda China today announced a $10 Million investment from Lilly Asian Ventures.

BioVeda China is the first international venture capital fund focusing on life sciences investments in China. The investment has shown Lilly's commitment to expand its economic footprint in the fast growing life science industry in China....   more»


Eli Lilly & Co »24/09/2007 [Company watch]
ELi Lilly to invest $10million in R & D in China

(What happened to the $100millions!) Eli Lilly & Co, the U.S. maker of antidepressant Prozac and erectile dysfunction drug Cialis, said its China sales were rising about 26 percent a year, on track to become the company's tenth biggest global market by 2010. "We're growing 10 percent faster than the market," Jorg Ostertag, president of Lilly China said over the weekend, adding that China's drug industry grew 16 percent in 2006. China is expected to become the world's No. 7 pharmaceutical market in 2012, and the second-biggest by 2020, Ostertag said at a conference at the China Europe International Business School. China now ranks as the company's 14th biggest market. Lilly has introduced five new drugs in China this year and expects to sell 15 more in the next five years, Osgtertag said. Lilly competes with Tamiflu maker Roche and Viagra producer Pfizer Inc to sell drugs in the world's most populous country. Lilly, which two years ago partnered with China's Hisun Group on drug development, has plans to start more such alliances with Chinese firms, he said. As early as Tuesday, Lilly will sign an agreement with a unit of Hutchison Whampoa on drug development. Hutchison, a conglomerate controlled by Hong Kong tycoon Li Ka-shing, owns businesses ranging from ports to telecoms and pharmaceuticals. In June, Lilly's Asia venture capital fund invested $10 million in Chinese startup BioVeda, and said it planned to invest $10 million on research and development in the country in the next five years....   more»


Eli Lilly & Co »08/11/2007 [Company watch]
Eli Lilly plans more drug development in China

U.S. pharmaceutical firm Eli Lilly & Co (LL.N:, maker of antidepressant Prozac and erectile dysfunction drug Cialis, said on Thursday it plans to develop more drugs in China because of lower costs and an ample pool of talent. "We need to find a way to establish leadership in China, not only by selling drugs," Darren Carroll, senior managing director of Lilly Asian Ventures, said in an interview. The cost for a researcher in China is as little as 20 percent of the cost in the United States, where one out of five of Lilly's researchers is Chinese, Carroll said. "We believe we should find ways to come to the innovators, rather than having them all come to the U.S."...   more»


Eli Lilly & Co »07/08/2008 [Company watch]
China makes small contribution to Lilly's profit growth

While global profit for Eli Lilly & Co. (NYSE:LLY) rose 31% to USD 958 million in the second fiscal quarter of 2008, the sales revenue from Lilly China comprised a relatively insignificant portion of global sales, according to Ming Cao, director of sales for Lilly China. China sales of Eli-Lilly's anti-impotence drug Cialis, for example, accounted for less than 1% of its 2007 global USD 1.2 billion revenue, and the firm does not expect the drug to become profitable in the country in the next five or six years. Cao added that although Lilly's China market is relatively small, it is growing at a robust 30% annually....   more»


Eli Lilly & Co »16/10/2008 [Company watch]
Eli Lilly & Co. Opens China R&D Headquarters in Shanghai

Eli Lilly & Co. announced that it set up a Chinese R&D headquarters in Shanghai. The Shanghai headquarters will organize a team that is responsible for R&D management and venture capital investments to seek, promote and manage the company's cooperation with Chinese companies and R&D institutes. In details, it will manage those outsourcing and risk-sharing R&D projects, transfers of alternative medicines and technologies, and VC investments in medical sector of the Greater China Region. The headquarters is located in the Shanghai Zhangjiang Hi-tech Park and nears bases of many of the company's partners. The new headquarters provides an important point of convergence for Lily's innovation network. Eli Lilly Mulls Acquisitions Eli Lilly & Co. said that there may be acquisition opportunities for the company in the next year or two. The company will look at expanding its presence in biotechnology. Chief Executive John Lechleiter, said: “Right now the biotech companies are probably going to struggle the most in this environment.” The chief said that: There would probably be opportunities for his company to pursue partnerships, acquisitions, licensing or other types of deals in the next year or two. “I think you can expect to see us be opportunistic,” he added. The company is also interested in expanding in areas such as oncology. “For the kinds of the things we'll need to do and for the kinds of acquisition we'll need to make, we believe between our cash position and our debt position we'll be able to execute on those,” he added. The Shanghai headquarters will organize a team that is responsible for R&D management and venture capital investments to seek, promote and manage the company's cooperation with Chinese companies and R&D institutes. In details, it will manage those outsourcing and risk-sharing R&D projects, transfers of alternative medicines and technologies, and VC investments in medical sector of the Greater China Region. The headquarters is located in the Shanghai Zhangjiang Hi-tech Park and nears bases of many of the company's partners. The new headquarters provides an important point of convergence for Lily's innovation network, said Robert Armstrong, Lily's vice president of global external R&D. Establishment of the headquarters indicates that the company intends to make in-depth investment in China and has growing confidence over Chinese companies' creativity, efficiency and capacity on biomedical R&D, said Bill Chin, vice president of Lily's discovery research and clinical investigation....   more»


Eli Lilly & Co »21/11/2008 [Company watch]
Hutchison China, Eli Lilly expand drug deal

(Reuters) - Hutchison China Meditech Ltd a traditional Chinese medicine-sourced pharmaceuticals maker, said on Friday it has expanded its drug discovery and development partnership with Eli Lilly and Co (focused on an additional target in oncology....   more»


Eli Lilly & Co »29/11/2008 [Company watch]
Lilly Adds Oncology Target to Chi-Med Collaboration

Eli Lilly has expanded its drug discovery and development partnership with Hutchison China Meditech Ltd, adding another oncology target to the agenda. When the two companies set up their partnership last year, the initial areas of concentration were specified targets in oncology and inflammation....   more»


Eli Lilly & Co »15/01/2009 [Company watch]
Eli Lilly settles Zyprexa suit for US$1.42 billion

Drugmaker Eli Lilly said Thursday it pleaded guilty to a charge that it illegally marketed anti-psychotic drug Zyprexa for off-label use, and will pay a combined US$1.42 billion to settle civil suits and end the criminal investigation....   more»


Eli Lilly & Co »14/04/2009 [Company watch]
Eli Lilly & Co Emphasizes China in Strategic Plan

Eli Lilly and Company will not attempt a large-scale merger similar to the ones currently in the big pharma news...   more»


Eli Lilly & Co »17/06/2009 [Company watch]
Lilly Offers Free Compound Testing in Collaboration with Lab Researchers

Eli Lilly has taken another step in implementing its transformation from a fully integrated big pharma to a partnership arrangement, which it now calls a Fully Integrated Pharmaceutical Network (FIPNet). The goal is to foster open collaboration between Lilly and global laboratory researchers....   more»


Eli Lilly & Co »21/09/2009 [Company watch]
Eli Lilly to Double China Workforce

Monday, September 21, 2009 David Ricks, president of Eli Lilly China, announced that although Eli Lilly will cut 5,500 jobs in the US, it will double its positions in China to over 2,000,...   more»


TOP NEWS
Eli Lilly & Co
»02/10/2009 [Company watch]
Eli Lilly will Double China Workforce

Eli Lilly plans to double its workforce inside of China this year, bringing the total up to 2,000. At the same time, the company announced a 5,500 employee reduction in its worldwide staff count that will help trim $1 billion in annual costs....   more»


TOP NEWS
Eli Lilly & Co
»14/12/2009 [Company watch]
Lilly Aims at the Growing China Pharmaceutical Market

In an annual review of its business plans, Eli Lilly (LLY) revealed China’s pharmaceutical market will be a top priority for the company....   more»


Eli Lilly & Co »30/03/2010 [Industry news]
Eli Lilly to invest aggressively in China

Eli Lilly to launch 15 new products in China in 5 yrs...   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.